Toward productive aging: SIRT1, Systemic NAD Biosynthesis, and the NAD world

Cornea

Volumn 29, Issue SUPPL. 1, 2010, Pages

  Imai, Shin Ichiro ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aging; metabolism; NAD biosynthesis; NAD World; NAMPT; productive aging; SIRT1; sirtuins

Indexed keywords

GLUCOSE; INSULIN; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINIC ACID; POTASSIUM CHLORIDE; SIRTUIN 1; TRYPTOPHAN;

AGING; BIOSYNTHESIS; CELL FUNCTION; CELL PROTECTION; CONFERENCE PAPER; GENE INACTIVATION; GENE OVEREXPRESSION; GLUCOSE HOMEOSTASIS; HEALTH CARE SYSTEM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; LONGEVITY; METABOLIC REGULATION; METABOLIC STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; QUALITY OF LIFE;

AGING; CYTOKINES; ENERGY METABOLISM; HUMANS; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SIRTUIN 1;

EID: 78649261395     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181ea4714     Document Type: Conference Paper

References (58)

1. National Institute of Population and Social Security Research. Population projections for Japan: 2006-2055, December 2006. Available at: Http:// www.ipss.go.jp/index-e.html. Accessed March 11, 2010.
2. Imai S. From heterochromatin islands to the NAD World: A hierarchical view of aging through the functions of mammalian Sirt1 and systemic NAD biosynthesis. Biochim Biophys Acta. 2009;1790:997-1004.
3. Imai S. The NAD World: A new systemic regulatory network for metabolism and aging-Sirt1, systemic NAD biosynthesis, and their importance. Cell Biochem Biophys. 2009;53:65-74.
4. Imai S. "Clocks" in the NAD World: NAD as a metabolic oscillator for the regulation of metabolism and aging. Biochim Biophys Acta. 2010; 1804:1584-1590.
5. Imai S, Guarente L. Ten years of NAD-dependent SIR2 family deacetylases: Implications for metabolic diseases. Trends Pharmacol Sci. 2010;31:212-220.
6. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004;73:417-435.
7. Dali-Youcef N, Lagouge M, Froelich S, et al. Sirtuins: The magnificent seven, function, metabolism and longevity. Ann Med. 2007;39:335-345.
8. Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell. 2006;126:257-268.
9. Schwer B, Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell Metab. 2008;7:104-112.
10. Astrom SU, Cline TW, Rine J. The Drosophila melanogaster sir2+ gene is nonessential and has only minor effects on position-effect variegation. Genetics. 2003;163:931-937.
11. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425: 191-196.
12. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 1999;13:2570-2580.
13. Rogina B, Helfand SL. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci U S A. 2004; 101:15998-16003.
14. Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature. 2001;410:227-230.
15. Wood JG, Rogina B, Lavu S, et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature. 2004;430:686-689.
16. Anderson RM, Bitterman KJ, Wood JG, et al. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature. 2003;423:181-185.
17. Lin S-J, Defossez P-A, Guarente L. Life span extension by calorie restriction in S. cerevisiae requires NAD and SIR2. Science. 2000;289: 2126-2128.
18. Lin S-J, Kaeberlein M, Andalis AA, et al. Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration. Nature. 2002;418:344-348.
19. Wang Y, Tissenbaum HA. Overlapping and distinct functions for a Caenorhabditis elegans SIR2 and DAF-16/FOXO. Mech Ageing Dev. 2006;127:48-56.
20. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007; 450:712-716.
21. Milne JC, Denu JM. The Sirtuin family: Therapeutic targets to treat diseases of aging. Curr Opin Chem Biol. 2008;12:11-17.
22. Westphal CH, Dipp MA, Guarente L. A therapeutic role for sirtuins in diseases of aging? Trends Biochem Sci. 2007;32:555-560.
23. Bordone L, Guarente L. Calorie restriction, SIRT1 and metabolism: Understanding longevity. Nat Rev Mol Cell Biol. 2005;6:298-305.
24. Imai S, Kiess W. Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes. Front Biosci. 2009;14:2983-2995.
25. Moynihan KA, Grimm AA, Plueger MM, et al. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab. 2005;2:105-117.
26. Bordone L, Motta MC, Picard F, et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol. 2006;4:e31.
27. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004;53(Suppl 3):S16-S21.
28. Ramsey KM, Mills KF, Satoh A, et al. Age-associated loss of Sirt1- mediated enhancement of glucose-stimulated insulin secretion in b cellspecific Sirt1-overexpressing (BESTO) mice. Aging Cell. 2008;7:78-88.
29. Kitamura YI, Kitamura T, Kruse JP, et al. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab. 2005;2:153-163.
30. Lee JH, Song MY, Song EK, et al. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes. 2009;58:344-351.
31. Richardson A, Liu F, Adamo ML, et al. The role of insulin and insulin-like growth factor-I in mammalian ageing. Best Pract Res Clin Endocrinol Metab. 2004;18:393-406.
32. Asher G, Gatfield D, Stratmann M, et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell. 2008;134:317-328.
33. +-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell. 2008;134:329-340.
34. Green CB, Takahashi JS, Bass J. The meter of metabolism. Cell. 2008; 134:728-742.
35. Ramsey KM, Marcheva B, Kohsaka A, et al. The clockwork of metabolism. Annu Rev Nutr. 2007;27:219-240.
36. + homeostasis in man. Cell Mol Life Sci. 2004;61:19-34.
37. Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol. 2007;23:164-170.
38. Rongvaux A, Andris F, Van Gool F, et al. Reconstructing eukaryotic NAD metabolism. Bioessays. 2003;25:683-690.
39. Ghislain M, Talla E, Francois JM. Identification and functional analysis of the Saccharomyces cerevisiae nicotinamidase gene, PNC1. Yeast. 2002; 19:215-324.
40. Khan JA, Tao X, Tong L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol. 2006;13:582-588.
41. Kim MK, Lee JH, Kim H, et al. Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866. J Mol Biol. 2006;362: 66-77.
42. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279:50754-50763.
43. Rongvaux A, Shea RJ, Mulks MH, et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol. 2002;32:3225-3234.
44. Wang T, Zhang X, Bheda P, et al. Structure of Nampt/PBEF/visfatin, a mammalian NAD(+) biosynthetic enzyme. Nat Struct Mol Biol. 2006; 13:661-662.
45. Imai S. Nicotinamide phosphoribosyltransferase (Nampt): A link between NAD biology, metabolism, and diseases. Curr Pharm Des. 2009;15: 20-28.
46. Revollo JR, Körner A, Mills KF, et al. Nampt/PBEF/visfatin regulates insulin secretion in b cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007;6:363-375.
47. Fulco M, Cen Y, Zhao P, et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell. 2008;14:661-673.
48. Ho C, Van Der Veer E, Akawi O, et al. SIRT1 markedly extends replicative lifespan if NAD(+) salvage is enhanced. FEBS Lett. 2009;583: 3081-3085.
49. + synthesis in cardiac myocytes. Circ Res. 2009;105:481-491.
50. + salvage pathway by CLOCK-SIRT1. Science. 2009;324:654-657.
51. + biosynthesis. Science. 2009;324: 651-654.
52. Skokowa J, Lan D, Thakur BK, et al. NAMPT is essential for the G-CSFinduced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat Med. 2009;15:151-158.
53. +-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res. 2005;97: 25-34.
54. + salvage pathway regulate SIRT1 activity at target gene promoters. J Biol Chem. 2009;284:20408-20417.
55. Basu R, Breda E, Oberg AL, et al. Mechanisms of the age-associated deterioration in glucose tolerance: Contribution of alterations in insulin secretion, action, and clearance. Diabetes. 2003;52:1738-1748.
56. Iozzo P, Beck-Nielsen H, Laakso M, et al. Independent influence of age on basal insulin secretion in nondiabetic humans. European Group for the Study of Insulin Resistance. J Clin Endocrinol Metab. 1999;84: 863-868.
57. Muzumdar R, Ma X, Atzmon G, et al. Decrease in glucose-stimulated insulin secretion with aging is independent of insulin action. Diabetes. 2004;53:441-446.
58. Williams AC Ramsden DB. Pellagra: A clue as to why energy failure causes diseases? Med Hypotheses. 2007;69:618-628.